Liver Cirrhosis Market Size, Growth Drivers, Opportunities, Industry Trends and Forecast to 2020

Posted on

Global Liver Cirrhosis Market 2016-2020 Report, published by Strategic Defense Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news.

Global Liver Cirrhosis Market of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

The Report analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Request a sample copy for Global Liver Cirrhosis Market Research Report @

The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

Global Liver Cirrhosis Market is divided into the following segments based on geography: Americas, APAC, EMEA

The report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Browse full table of contents and data tables at

Global Liver Cirrhosis Market Key Vendor’s F Hoffman La-Roche, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Merck

Global Liver Cirrhosis Market Other prominent vendors Bristol-Myers Squibb, Conatus Pharmaceuticals, Gwo Xi Stem Cell Applied Technology, Instituto Grifols, Intercept Pharmaceuticals, NGM Biopharmaceuticals

Request Discount for Global Liver Cirrhosis Market Research Report @

Related Report:

EpiCast Report: Hepatitis C Virus – Epidemiology Forecast to 2025 @

Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV can cause both acute and chronic hepatitis infection. According to the World Health Organization (WHO), an estimated 130-150 million individuals worldwide are affected with chronic HCV and about 500,000 people died of HCV-related conditions, including liver cirrhosis and hepatocellular carcinoma (HCC), in 2010 (Lozano et al., 2012; WHO, 2015).

Hepatitis B Virus (HBV) Therapeutics – 5EU Drug Forecast and Market Analysis to 2024 @

Chronic hepatitis B virus (HBV) infection is a serious chronic liver disease caused by the failure of viral clearance following acute HBV infection. Despite the availability of effective prophylactic vaccines, the disease remains a serious global health concern, with estimated over 350 million people worldwide currently living with this condition.

About Us:

Centralize market research purchases across your entire organization in one allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

Contact Us:

Market Study Report

The Green Suite #4594,

Dover, DE 19901

United States

Phone: 1-201-355-0868

US Toll Free: 1-866-764-2150



Connect with us: Google+ | LinkedIn | Twitter